{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T19:32:07Z","timestamp":1794684727327,"version":"4.9.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","award":["18\/SPP\/3522"],"award-info":[{"award-number":["18\/SPP\/3522"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001593","name":"Irish Cancer Society","doi-asserted-by":"publisher","award":["CCRC13GAL"],"award-info":[{"award-number":["CCRC13GAL"]}],"id":[{"id":"10.13039\/501100001593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Female patients with ER\n                    <jats:sup>+<\/jats:sup>\n                    HER2\n                    <jats:sup>-<\/jats:sup>\n                    breast cancer have a favourable prognosis for 5-10 years. Later relapses are, however, common, yet predictions of late recurrence risk are suboptimal, particularly for patients with intermediate risk determined by the Oncotype Dx Recurrence Score (RS, 16-25). Here, we analyse tissue samples from patients with ER\n                    <jats:sup>+<\/jats:sup>\n                    HER2\n                    <jats:sup>-<\/jats:sup>\n                    breast cancer using spatial proteomics (multiplex immunofluorescence with 5 markers,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009440) and spatial transcriptomics (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009359), and find decoupled immune states between stroma and epithelia. Moreover, inflamed stroma express genes linked to tissue remodelling, immune exhaustion, and inhibitory\/checkpoint receptors (\n                    <jats:italic>CTLA4, TIGIT, CD96<\/jats:italic>\n                    ); inflamed epithelia similarly express genes associated with checkpoints (\n                    <jats:italic>CTLA4<\/jats:italic>\n                    ) and exhaustion (\n                    <jats:italic>CXCL13<\/jats:italic>\n                    ), but also genes attributed to antigen presentation. In our randomised, Intermediate RS cohort treated with chemotherapy we observe an association between higher stromal tumour-infiltrating CD8\n                    <jats:sup>+<\/jats:sup>\n                    lymphocyte (sTIL CD8\n                    <jats:sup>+<\/jats:sup>\n                    ) density and poor outcome (\u0394LR-\u03c7\n                    <jats:sup>2<\/jats:sup>\n                    : 6.79,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.009), which we validate using data from whole-resection specimens (\u0394LR-\u03c7\n                    <jats:sup>2<\/jats:sup>\n                    : 8.90,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003). Our data thus provide insights into the immune states in ER\n                    <jats:sup>+<\/jats:sup>\n                    HER2\n                    <jats:sup>-<\/jats:sup>\n                    breast cancer, and propose sTIL CD8\n                    <jats:sup>+<\/jats:sup>\n                    density as candidate biomarker for treatment decisions.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-73432-2","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:23:52Z","timestamp":1782206632000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Spatial analyses implicate high stromal tumour-infiltrating CD8+ lymphocytes as a negative predictive marker for chemotherapy in estrogen receptor-positive breast cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6176-8895","authenticated-orcid":false,"given":"Zak","family":"Kinsella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chowdhury Arif","family":"Jahangir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Nyarkoah","family":"Nyarko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8440-6168","authenticated-orcid":false,"given":"Daria","family":"Kalinska-Lysiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Aura","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"O\u2019Grady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Fay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Sheehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Crown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3024-4773","authenticated-orcid":false,"given":"Simon S.","family":"McDade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh M. C.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3479-7794","authenticated-orcid":false,"given":"Jochen H. M.","family":"Prehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8835-1547","authenticated-orcid":false,"given":"Darran P.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"73432_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","volume":"28","author":"C Denkert","year":"2010","unstructured":"Denkert, C. et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28, 105\u201313 (2010).","journal-title":"J. Clin. Oncol."},{"key":"73432_CR2","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","volume":"25","author":"S Loi","year":"2014","unstructured":"Loi, S. et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann. Oncol. 25, 1544\u201350 (2014).","journal-title":"Ann. Oncol."},{"key":"73432_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 26, 259\u201371 (2015).","journal-title":"Ann. Oncol."},{"key":"73432_CR4","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cell.2019.03.005","volume":"177","author":"J Wagner","year":"2019","unstructured":"Wagner, J. et al. A single-cell atlas of the tumor and immune ecosystem of human breast cancer. Cell 177, 1330\u201345 (2019).","journal-title":"Cell"},{"key":"73432_CR5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346\u201352 (2012).","journal-title":"Nature"},{"key":"73432_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s43018-020-0026-6","volume":"1","author":"HR Ali","year":"2020","unstructured":"Ali, H. R. et al. Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer. Nat. Cancer 1, 163\u201375 (2020).","journal-title":"Nat. Cancer"},{"key":"73432_CR7","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41588-022-01041-y","volume":"54","author":"E Danenberg","year":"2022","unstructured":"Danenberg, E. et al. Breast tumor microenvironment structures are associated with genomic features and clinical outcome. Nat. Genet. 54, 660\u20139 (2022).","journal-title":"Nat. Genet."},{"key":"73432_CR8","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","volume":"31","author":"S Loi","year":"2025","unstructured":"Loi, S. et al. Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. Nat. Med. 31, 433\u201341 (2025).","journal-title":"Nat. Med."},{"key":"73432_CR9","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1200\/JCO.23.02614","volume":"42","author":"A R\u00edos-Hoyo","year":"2024","unstructured":"R\u00edos-Hoyo, A. et al. Neoadjuvant chemotherapy and immunotherapy for estrogen receptor\u2013positive human epidermal growth factor 2\u2013negative breast cancer. J. Clin. Oncol. 42, 2632\u20136 (2024).","journal-title":"J. Clin. Oncol."},{"key":"73432_CR10","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","volume":"31","author":"F Cardoso","year":"2025","unstructured":"Cardoso, F. et al. Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2\u2212 breast cancer: a randomized phase 3 trial. Nat. Med. 31, 442\u20138 (2025).","journal-title":"Nat. Med."},{"key":"73432_CR11","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","volume":"25","author":"HR Ali","year":"2014","unstructured":"Ali, H. R. et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients. Ann. Oncol. 25, 1536\u201343 (2014).","journal-title":"Ann. Oncol."},{"key":"73432_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0432-8","volume":"16","author":"S Liu","year":"2014","unstructured":"Liu, S. et al. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res. 16, 432 (2014).","journal-title":"Breast Cancer Res."},{"key":"73432_CR13","doi-asserted-by":"publisher","first-page":"17462","DOI":"10.18632\/oncotarget.3958","volume":"6","author":"Y Huang","year":"2015","unstructured":"Huang, Y. et al. CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome. Oncotarget 6, 17462\u201378 (2015).","journal-title":"Oncotarget"},{"key":"73432_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/srep15179","volume":"5","author":"B Shang","year":"2015","unstructured":"Shang, B., Liu, Y., Jiang, S. -j & Liu, Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci. Rep. 5, 15179 (2015).","journal-title":"Sci. Rep."},{"key":"73432_CR15","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s43018-023-00527-w","volume":"4","author":"S Onkar","year":"2023","unstructured":"Onkar, S. et al. Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment. Nat. Cancer 4, 516\u201334 (2023).","journal-title":"Nat. Cancer"},{"key":"73432_CR16","doi-asserted-by":"crossref","unstructured":"O\u2019Meara, T. et al. Immunological differences between immune-rich estrogen receptor\u2013positive and immune-rich triple-negative breast cancers. JCO Precis. Oncol. 3, 767\u2013779 (2020).","DOI":"10.1200\/PO.19.00350"},{"key":"73432_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00416-y","volume":"8","author":"I Nederlof","year":"2022","unstructured":"Nederlof, I. et al. Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer. NPJ Breast Cancer 8, 56 (2022).","journal-title":"NPJ Breast Cancer"},{"key":"73432_CR18","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","volume":"375","author":"F Cardoso","year":"2016","unstructured":"Cardoso, F. et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. New Engl. J. Med. 375, 717\u201329 (2016).","journal-title":"New Engl. J. Med."},{"key":"73432_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano, J. A. et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. New Engl. J. Med. 379, 111\u201321 (2018).","journal-title":"New Engl. J. Med."},{"key":"73432_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20100","volume":"20","author":"RC Stein","year":"2016","unstructured":"Stein, R. C. et al. OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. Health Technol. Assess. 20, 1\u2013201 (2016).","journal-title":"Health Technol. Assess."},{"key":"73432_CR21","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1038\/sj.bjc.6603498","volume":"95","author":"MER O\u2019Brien","year":"2006","unstructured":"O\u2019Brien, M. E. R. et al. Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients. Br. J. Cancer 95, 1632\u20136 (2006).","journal-title":"Br. J. Cancer"},{"key":"73432_CR22","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1200\/JCO.2017.76.3441","volume":"36","author":"W van Dorp","year":"2018","unstructured":"van Dorp, W. et al. Reproductive function and outcomes in female survivors of childhood, adolescent, and young adult cancer: a review. J. Clin. Oncol. 36, 2169\u201380 (2018).","journal-title":"J. Clin. Oncol."},{"key":"73432_CR23","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1200\/JCO.18.02433","volume":"37","author":"MM Regan","year":"2019","unstructured":"Regan, M. M., Fleming, G. F., Walley, B., Francis, P. A. & Pagani, O. Adjuvant systemic treatment of premenopausal women with hormone receptor-positive early breast cancer: lights and shadows. J. Clin. Oncol. 37, 862\u20136 (2019).","journal-title":"J. Clin. Oncol."},{"key":"73432_CR24","first-page":"1","volume":"41","author":"I Vaz-Luis","year":"2021","unstructured":"Vaz-Luis, I., Francis, P. A., Di Meglio, A. & Stearns, V. Challenges in adjuvant therapy for premenopausal women diagnosed with luminal breast cancers. Am. Soc. Clin. Oncol. Educ. Book 41, 1\u201315 (2021).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"73432_CR25","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/nmeth.4077","volume":"13","author":"D T\u00fcrei","year":"2016","unstructured":"T\u00fcrei, D., Korcsm\u00e1ros, T. & Saez-Rodriguez, J. OmniPath: guidelines and gateway for literature-curated signaling pathway resources. Nat. Methods 13, 966\u20137 (2016).","journal-title":"Nat. Methods"},{"key":"73432_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35238-w","volume":"14","author":"S Tietscher","year":"2023","unstructured":"Tietscher, S. et al. A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer. Nat. Commun. 14, 98 (2023).","journal-title":"Nat. Commun."},{"key":"73432_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18794-x","volume":"11","author":"J Winkler","year":"2020","unstructured":"Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J. & Werb, Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat. Commun. 11, 5120 (2020).","journal-title":"Nat. Commun."},{"key":"73432_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00695-7","volume":"10","author":"SM Cha","year":"2024","unstructured":"Cha, S. M. et al. SPP1+ macrophages in HR+ breast cancer are associated with tumor-infiltrating lymphocytes. NPJ Breast Cancer 10, 83 (2024).","journal-title":"NPJ Breast Cancer"},{"key":"73432_CR29","doi-asserted-by":"crossref","unstructured":"Sun, Q. & Dong, C. Regulators of CD8+ T cell exhaustion. Nat. Rev. Immunol. 26, 129\u2013151 (2025).","DOI":"10.1038\/s41577-025-01221-x"},{"key":"73432_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui, I. et al. Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195\u2013211 (2019).","journal-title":"Immunity"},{"key":"73432_CR31","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1084\/jem.20100619","volume":"208","author":"L Wang","year":"2011","unstructured":"Wang, L. et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 208, 577\u201392 (2011).","journal-title":"J. Exp. Med."},{"key":"73432_CR32","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1158\/0008-5472.CAN-13-1506","volume":"74","author":"I Le Mercier","year":"2014","unstructured":"Le Mercier, I. et al. VISTA regulates the development of protective antitumor immunity. Cancer Res. 74, 1933\u201344 (2014).","journal-title":"Cancer Res."},{"key":"73432_CR33","doi-asserted-by":"crossref","unstructured":"Vanmeerbeek, I. et al. Targeting conserved TIM3+VISTA+ tumor-associated macrophages overcomes resistance to cancer immunotherapy. Sci. Adv. 10, eadm8660 (2024).","DOI":"10.1126\/sciadv.adm8660"},{"key":"73432_CR34","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1158\/1078-0432.CCR-18-3200","volume":"25","author":"ML Axelrod","year":"2019","unstructured":"Axelrod, M. L., Cook, R. S., Johnson, D. B. & Balko, J. M. Biological consequences of MHC-II expression by tumor cells in cancer. Clin. Cancer Res. 25, 2392\u2013402 (2019).","journal-title":"Clin. Cancer Res."},{"key":"73432_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114906","volume":"160","author":"L Hou","year":"2025","unstructured":"Hou, L. et al. Targeting SPP1+ macrophages via the SPP1-CD44 axis reveals a key mechanism of immune suppression and tumor progression in ovarian cancer. Int. Immunopharmacol. 160, 114906 (2025).","journal-title":"Int. Immunopharmacol."},{"key":"73432_CR36","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/s43018-024-00775-4","volume":"5","author":"KM Tharp","year":"2024","unstructured":"Tharp, K. M. et al. Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment. Nat. Cancer 5, 1045\u201362 (2024).","journal-title":"Nat. Cancer"},{"key":"73432_CR37","doi-asserted-by":"crossref","unstructured":"Egelston, C. A. et al. Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor\u2013positive breast cancer. JCI Insight 7, e153963 (2022).","DOI":"10.1172\/jci.insight.153963"},{"key":"73432_CR38","doi-asserted-by":"crossref","unstructured":"Rozenblit, M. et al. PD-L1 protein expression in relation to recurrence score values in early-stage ER+ breast cancer. Breast Cancer Res. Treat. 196, 221\u2013227 (2022).","DOI":"10.1007\/s10549-022-06712-2"},{"key":"73432_CR39","doi-asserted-by":"crossref","unstructured":"Chervoneva, I. et al. High PD-L2 predicts early recurrence of ER-positive breast cancer. JCO Precis. Oncol. 7, e2100498 (2023).","DOI":"10.1200\/PO.21.00498"},{"key":"73432_CR40","doi-asserted-by":"publisher","first-page":"S1260","DOI":"10.1016\/j.annonc.2023.10.011","volume":"34","author":"F Cardoso","year":"2023","unstructured":"Cardoso, F. et al. LBA21 KEYNOTE-756: phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+\/HER2\u2013 breast cancer. Ann. Oncol. 34, S1260\u2013S1 (2023).","journal-title":"Ann. Oncol."},{"key":"73432_CR41","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","volume":"6","author":"R Nanda","year":"2020","unstructured":"Nanda, R. et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 6, 676\u201384 (2020).","journal-title":"JAMA Oncol."},{"key":"73432_CR42","unstructured":"Wolf, D. M. et al. Immune subtyping identifies patients with hormone receptor\u2013positive early-stage breast cancer who respond to neoadjuvant immunotherapy (IO): results from five IO arms of the I-SPY2 trial. JCO Precis. Oncol. 9, e2400776 (2025)."},{"key":"73432_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66667-y","volume":"16","author":"AG Waks","year":"2025","unstructured":"Waks, A. G. et al. Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: a randomized pilot trial. Nat. Commun. 16, 10705 (2025).","journal-title":"Nat. Commun."},{"key":"73432_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00698-4","volume":"10","author":"J Dixon-Douglas","year":"2024","unstructured":"Dixon-Douglas, J. et al. Sustained lymphocyte decreases after treatment for early breast cancer. NPJ Breast Cancer 10, 94 (2024).","journal-title":"NPJ Breast Cancer"},{"key":"73432_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19933-0","volume":"11","author":"YH Park","year":"2020","unstructured":"Park, Y. H. et al. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. Nat. Commun. 11, 6175 (2020).","journal-title":"Nat. Commun."},{"key":"73432_CR46","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1126\/science.1208347","volume":"334","author":"M Michaud","year":"2011","unstructured":"Michaud, M. et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334, 1573\u20137 (2011).","journal-title":"Science"},{"key":"73432_CR47","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi, L., Humeau, J., Buqu\u00e9, A., Zitvogel, L. & Kroemer, G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17, 725\u201341 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"73432_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33598-x","volume":"13","author":"L Monteran","year":"2022","unstructured":"Monteran, L. et al. Chemotherapy-induced complement signaling modulates immunosuppression and metastatic relapse in breast cancer. Nat. Commun. 13, 5797 (2022).","journal-title":"Nat. Commun."},{"key":"73432_CR49","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","volume":"373","author":"JA Sparano","year":"2015","unstructured":"Sparano, J. A. et al. Prospective validation of a 21-gene expression assay in breast cancer. New Engl. J. Med. 373, 2005\u201314 (2015).","journal-title":"New Engl. J. Med."},{"key":"73432_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-018-0063-9","volume":"4","author":"JA Sparano","year":"2018","unstructured":"Sparano, J. A. Prognostic gene expression assays in breast cancer: are two better than one? NPJ Breast Cancer 4, 11 (2018).","journal-title":"NPJ Breast Cancer"},{"key":"73432_CR51","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1200\/JCO.20.03613","volume":"39","author":"SM Tolaney","year":"2021","unstructured":"Tolaney, S. M. et al. Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0. J. Clin. Oncol. 39, 2720\u201331 (2021).","journal-title":"J. Clin. Oncol."},{"key":"73432_CR52","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41587-020-0472-9","volume":"38","author":"CR Merritt","year":"2020","unstructured":"Merritt, C. R. et al. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat. Biotechnol. 38, 586\u201399 (2020).","journal-title":"Nat. Biotechnol."},{"key":"73432_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"73432_CR54","doi-asserted-by":"crossref","unstructured":"Schmidt, U, Weigert, M., Broaddus, C. & Myers, G. (eds). Cell detection with star-convex polygons. In Proc. Medical Image Computing and Computer Assisted Intervention, MICCAI 2018 (Springer International Publishing, 2018).","DOI":"10.1007\/978-3-030-00934-2_30"},{"key":"73432_CR55","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","volume":"45","author":"L Breiman","year":"2001","unstructured":"Breiman, L. Random forests. Mach. Learn. 45, 5\u201332 (2001).","journal-title":"Mach. Learn."},{"key":"73432_CR56","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2021.04.016","volume":"152","author":"SM Lynch","year":"2021","unstructured":"Lynch, S. M. et al. Prognostic value of the 6-gene OncoMasTR test in hormone receptor\u2013positive HER2-negative early-stage breast cancer: comparative analysis with standard clinicopathological factors. Eur. J. Cancer 152, 78\u201389 (2021).","journal-title":"Eur. J. Cancer"},{"key":"73432_CR57","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41409-019-0679-x","volume":"55","author":"J Gauthier","year":"2020","unstructured":"Gauthier, J., Wu, Q. V. & Gooley, T. A. Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians. Bone Marrow Transplant. 55, 675\u201380 (2020).","journal-title":"Bone Marrow Transplant."},{"key":"73432_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s41512-019-0064-7","volume":"3","author":"AJ Vickers","year":"2019","unstructured":"Vickers, A. J., van Calster, B. & Steyerberg, E. W. A simple, step-by-step guide to interpreting decision curve analysis. Diagn. Progn. Res. 3, 18 (2019).","journal-title":"Diagn. Progn. Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73432-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73432-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73432-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:24:10Z","timestamp":1782206650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73432-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73432"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73432-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.M.G. is a co-founder, shareholder and part-time employee of OncoAssure Limited, along with being a shareholder of Deciphex Limited. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4863"}}